Novavax, Inc.

NASDAQ:NVAX   3:59:50 PM EDT
134.58
-4.21 (-3.03%)
4:14:24 PM EDT: $134.56 -0.02 (-0.02%)
Products, Regulatory

Results From Novavax Nanoflu Influenza Vaccine Phase 3 Clinical Trial Published In Lancet Infectious Diseases

Published: 09/24/2021 00:19 GMT
Novavax, Inc. (NVAX) - Results From Novavax Nanoflu Influenza Vaccine Phase 3 Clinical Trial Published in Lancet Infectious Diseases.
Novavax - Results From Nanoflu Influenza Vaccine Phase 3 Clinical Trial Achieved All Primary Endpoints.
Novavax Inc - Nanoflu Vaccine Candidate Induced Significantly Enhanced Cell-mediated Immune Responses.
Novavax Inc - Nanoflu Was Well-tolerated With a Comparable Safety Profile.